Clinical Trial Update: Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating a triplet regimen of isatuximab, carfilzomib, and pomalidomide for relapsed or refractory multiple myeloma; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• Isatuximab (isatuximab)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING